133 related articles for article (PubMed ID: 35108359)
21. Inhibition of Pim2-prolonged skin allograft survival through the apoptosis regulation pathway.
Liu H; Zhang C; Liang T; Song J; Hao J; Hou G
Cell Mol Immunol; 2012 Nov; 9(6):503-10. PubMed ID: 23085945
[TBL] [Abstract][Full Text] [Related]
22. Proviral integration site 2 is required for interleukin-6 expression induced by interleukin-1, tumour necrosis factor-α and lipopolysaccharide.
Yang J; Li X; Hanidu A; Htut TM; Sellati R; Wang L; Jiang H; Li J
Immunology; 2010 Oct; 131(2):174-82. PubMed ID: 20465571
[TBL] [Abstract][Full Text] [Related]
23. Proviral insertion in murine lymphomas 2 promotes stomach cancer progression by regulating apoptosis via reactive oxygen species-triggered endoplasmic reticulum stress.
Xin H; Deng Y; Cao J
Biochem Biophys Res Commun; 2018 Nov; 506(1):145-152. PubMed ID: 30340823
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics.
Wang Y; Xiu J; Ren C; Yu Z
J Cancer; 2021; 12(9):2570-2581. PubMed ID: 33854618
[TBL] [Abstract][Full Text] [Related]
25. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.
Whillock AL; Mambetsariev N; Lin WW; Stunz LL; Bishop GA
Sci Rep; 2019 Sep; 9(1):12884. PubMed ID: 31501481
[TBL] [Abstract][Full Text] [Related]
26. PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.
Tang X; Cao T; Zhu Y; Zhang L; Chen J; Liu T; Ming X; Fang S; Yuan YF; Jiang L; Huang JD; Guan XY
Cell Death Dis; 2020 Jul; 11(7):510. PubMed ID: 32641749
[TBL] [Abstract][Full Text] [Related]
27. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
Burger MT; Han W; Lan J; Nishiguchi G; Bellamacina C; Lindval M; Atallah G; Ding Y; Mathur M; McBride C; Beans EL; Muller K; Tamez V; Zhang Y; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Holash J; Castillo J; Langowski J; Wang Y; Chen MY; Garcia PD
ACS Med Chem Lett; 2013 Dec; 4(12):1193-7. PubMed ID: 24900629
[TBL] [Abstract][Full Text] [Related]
28. Expression of the PIM2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia.
Kapelko-Słowik K; Dybko J; Grzymajło K; Jaźwiec B; Urbaniak-Kujda D; Słowik M; Potoczek S; Wołowiec D
Adv Clin Exp Med; 2019 Mar; 28(3):385-390. PubMed ID: 30525315
[TBL] [Abstract][Full Text] [Related]
29. RAG-induced DNA double-strand breaks signal through Pim2 to promote pre-B cell survival and limit proliferation.
Bednarski JJ; Nickless A; Bhattacharya D; Amin RH; Schlissel MS; Sleckman BP
J Exp Med; 2012 Jan; 209(1):11-7. PubMed ID: 22201128
[TBL] [Abstract][Full Text] [Related]
30. Abrine promotes cell proliferation and inhibits apoptosis of interleukin-1β-stimulated chondrocytes via PIM2/VEGF signalling in osteoarthritis.
Meng Y; Yin D; Qiu S; Zhang X
Phytomedicine; 2022 Feb; 96():153906. PubMed ID: 35026522
[TBL] [Abstract][Full Text] [Related]
31. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.
Agrawal-Singh S; Koschmieder S; Gelsing S; Stocking C; Stehling M; Thiede C; Thoennissen NH; Köhler G; Valk PJ; Delwel R; Mills K; Bäumer N; Tickenbrock L; Hansen K; Berdel WE; Müller-Tidow C; Serve H
Blood; 2010 Jun; 115(22):4507-16. PubMed ID: 20215640
[TBL] [Abstract][Full Text] [Related]
32. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
33. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
34. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
35. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of PIM2 by Underexpression of MicroRNA-135-5p Improves Survival Rates of Skin Allografts by Suppressing Apoptosis of Fibroblast Cells.
Zhang H
Med Sci Monit; 2017 Jan; 23():107-113. PubMed ID: 28064305
[TBL] [Abstract][Full Text] [Related]
37. Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Chulanetra M; Seesuay W; Chaicumpa W; Sookrung N
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770845
[TBL] [Abstract][Full Text] [Related]
38. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines.
Li YY; Popivanova BK; Nagai Y; Ishikura H; Fujii C; Mukaida N
Cancer Res; 2006 Jul; 66(13):6741-7. PubMed ID: 16818649
[TBL] [Abstract][Full Text] [Related]
39. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
Jöhrer K; Obkircher M; Neureiter D; Parteli J; Zelle-Rieser C; Maizner E; Kern J; Hermann M; Hamacher F; Merkel O; Wacht N; Zidorn C; Scheideler M; Greil R
J Mol Med (Berl); 2012 Jun; 90(6):681-93. PubMed ID: 22205266
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
Kassambara A; Schoenhals M; Moreaux J; Veyrune JL; Rème T; Goldschmidt H; Hose D; Klein B
PLoS One; 2013; 8(4):e62752. PubMed ID: 23646139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
